Literature DB >> 20940284

Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection.

Haijun Zhou1, Hua Huang, Jiong Shi, Yue Zhao, Qiongzhu Dong, Huliang Jia, Yinkun Liu, Qinghai Ye, Huichuan Sun, Xiaodong Zhu, Liyun Fu, Kun Guo, Dongmei Gao, Jian Sun, Zhaowei Yan, Ning Ren, Zhaoyou Tang, Lunxiu Qin.   

Abstract

BACKGROUND AND AIMS: Th1/Th2-like cytokine mRNA levels in non-cancerous hepatic tissues from patients with hepatocellular carcinoma (HCC) are associated with metastases and recurrence. This study evaluated the prognostic values of intratumoral and peritumoral Th1/Th2 cytokine protein levels in patients with HCC after curative resection.
METHODS: Two independent cohorts (A and B) of 453 patients with HCC were enrolled. Twelve Th1/Th2 cytokines in tumour and peritumoral hepatic tissues from cohort A (n=192) were quantified with enzyme-linked immunosorbent assays. This cohort was split into training and test sets which were used to identify and verify the prognostic cytokines. The prognostic values of identified cytokines were further validated in cohort B (n=261) using tissue microarray and immunohistochemical staining.
RESULTS: In the training set, higher interleukin (IL)-2 and IL-15 levels in peritumoral liver tissues, but not in tumour tissues, were significantly associated with a decreased incidence of recurrence of intrahepatic tumour and a prolonged overall survival. This association was verified in the testing set and further validated in patients in cohort B. Importantly, this correlation remained significant in patients with early HCC. Univariate and multivariate analyses indicated that the prognostic performance of peritumoral IL-2 (HR for recurrence=0.4, 95% CI 0.3 to 0.6, p<0.0001; HR for death=0.6, 95% CI 0.4 to 0.8, p=0.005) and IL-15 (HR for recurrence=0.7, 95% CI 0.5 to 0.95, p=0.025) was independent of other clinicopathological factors.
CONCLUSION: Peritumoral IL-2 and IL-15 levels are useful for stratifying patients, even those with early-stage HCC, into subgroups with different prognoses after curative resection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940284     DOI: 10.1136/gut.2010.218404

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection.

Authors:  Xiangjiu Ding; Kexin Wang; Hui Wang; Guangyong Zhang; Yajing Liu; Qingyun Yang; Weijie Chen; Sanyuan Hu
Journal:  J Gastrointest Surg       Date:  2011-11-10       Impact factor: 3.452

2.  Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma.

Authors:  Jinyan Zhang; Tao Huang; Fan Zhang; Junming Xu; Guoqing Chen; Xiaoliang Wang; Li Huang; Zhihai Peng
Journal:  Tumour Biol       Date:  2015-03-19

3.  Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma.

Authors:  Rui Liao; Tai-Wei Sun; Yong Yi; Han Wu; Yi-Wei Li; Jia-Xing Wang; Jian Zhou; Ying-Hong Shi; Yun-Feng Cheng; Shuang-Jian Qiu; Jia Fan
Journal:  Cancer Sci       Date:  2012-04-19       Impact factor: 6.716

Review 4.  Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma.

Authors:  Yi-Fang Han; Jun Zhao; Li-Ye Ma; Jian-Hua Yin; Wen-Jun Chang; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

5.  Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma.

Authors:  Lun-Xiu Qin
Journal:  Cancer Microenviron       Date:  2012-06-08

Review 6.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

7.  Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses.

Authors:  Liang Cheng; Xuexiang Du; Zheng Wang; Jianqi Ju; Mingming Jia; Qibin Huang; Qiao Xing; Meng Xu; Yi Tan; Mingyue Liu; Peishuang Du; Lishan Su; Shengdian Wang
Journal:  J Hepatol       Date:  2014-07-10       Impact factor: 25.083

8.  SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.

Authors:  H Zhou; Y Qin; S Ji; J Ling; J Fu; Z Zhuang; X Fan; L Song; X Yu; P J Chiao
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

9.  The Histologic Cut-off Point for Adjacent and Remote Non-neoplastic Liver Parenchyma of Hepatocellular Carcinoma in Chronic Hepatitis B Patients.

Authors:  Hae Yoen Jung; Soo Hee Kim; Jin Jing; Jae Moon Gwak; Chul Ju Han; Ja-June Jang; Kyoung-Bun Lee
Journal:  Korean J Pathol       Date:  2012-08-23

Review 10.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.

Authors:  Cheng Sun; Haoyu Sun; Cai Zhang; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2014-10-13       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.